The true cost of “free” samples
Many physicians see drug samples as a benefit, because they can give pills to patients who may not be able to afford the medication otherwise. But are these "free" samples really free? More
New Alzheimer’s drug: Game-changing or underwhelming?
When it comes to dementia and Alzheimer's Disease, it appears that anxiety about cognitive decline is driving treatment decisions, rather than evidence. More
More doctors than ever are pharma-made millionaires
Is sunshine really the best disinfectant? Or do we need much more than transparency when it comes to financial conflicts of interest? More
This year’s spoooooookiest pharma ads
It's a Lown Institute tradition to highlight pharma's fear-mongering on Halloween, and this year is no exception. More
Is this $2 million gene therapy drug priced “fairly”?
The approval of a new gene therapy to treat spinal muscular atrophy has created a hot debate in the health policy world about whether or not the drug's $2.1 million price tag is too expensive or a fair price. More
Are government agency workers “here for the right reasons”?
Why the revolving door poses a serious problem for government agency regulation. More
Esketamine nears FDA approval, prompting both excitement and concern
As the powerful depression drug esketamine nearly FDA approval, some researchers are concerned that the approval would be lowering the bar for clinical evidence. More
The moral price we pay for “innovation”
Our willingness to turn a blind eye to the profiteering of biotech is a moral failing, writes Dr. Vikas Saini in a Commonhealth op-ed. More
Benzos increasingly prescribed for dubious indications, study shows
A new study sheds finds that benzodiazepine are being increasingly prescribed chronic pain and long-term use, which may have harmful consequences. More
In pharmaceutical marketing, a little goes a long way
A new study shows that in pharmaceutical marketing, the number of doctors you target may matter more than the amount of money you give them. More
Treats or tricks? Scary pharma ads, part 2
Halloween is time for costumes, spooky stories, and... drug advertisements? More
Without full data, Vascepa trial results still a little bit fishy
Are omega-3 supplements the "new paradigm" in cardiovascular treatment? Not yet... More
One drug, 247 patents, $18 billion
A new report reveals how drugmaker Abbvie has abused the patent system to delay competition for its bestselling drug. More
Industry payments to doctors: Opioids are the tip of the iceberg
A closer look at the hundreds of millions that pharma spends on payments to physicians. More
Industry payments to doctors: Opioids are the tip of the iceberg
A closer look at the hundreds of millions that pharma spends on payments to physicians. More
Health care? More like health scare!
Every day is Halloween for pharma marketers... More